Implication of integrin α5β1 in human breast carcinoma apoptosis and drug resistance

Biomeditsinskaya Khimiya

Volumn 57, Issue 1, 2011, Pages 77-84

  Morozevich, G E ^a   Kozlova, N I ^a   Ushakova, N A ^a   Preobrazhenskaya, M E ^a   Berman, A E ^a  

^a INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

Author keywords

Anoikis; Drug resistance; Integrins; Signal protein kinases

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; DOXORUBICIN; TUMOR PROTEIN; VERY LATE ACTIVATION ANTIGEN 5;

APOPTOSIS; ARTICLE; BREAST TUMOR; DRUG EFFECT; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTEGRIN ALPHA5BETA1; NEOPLASM PROTEINS; SIGNAL TRANSDUCTION;

EID: 79955895718     PISSN: 23106905     EISSN: None     Source Type: Journal    
DOI: 10.18097/pbmc20115701077     Document Type: Article

References (25)

1. Marastoni S., Ligresti G., Lorenzon E., Colombatt A., Mongiat M. (2008) Con. Tis. Res., 49, 203-206.
2. Hynes R.O. (2009) Science, 326, 1216-1219.
3. Chiarugi P., Giannoni E. (2008) Biochem. Pharmac., 76, 1352-1364.
4. Elliott T, Sethi T. (2002) Expert. Rev. Anticancer Then, 2, 449-459.
5. Cheresh D.A., Stupack D.G. (2002) Nature Med., 8, 193-194.
6. Desgrosellier JS, Cheresh D.A. (2010) Nat. Rev. Cancer, 10, 9-22.
7. Chrenek M.A., Wong P., Weaver V.M. (2001) Breast Cancer Res., 3, 224-229.
8. Damiano J.S. (2002) Curr. Cancer Drug Targets, 2, 37-43.
9. Kozlova N.I., Morozevich G.E., Chubukina A.N., Berman A.E. (2001) Oncogene, 20, 4710-4717.
10. Fuente M.T., Casanova B., Cantero E., del Cerro M.H., Garcia-Marco J., Silva A., Garcia-Pardo A. (2003) Biochem. Biophys. Res. Communs., 311, 708-712.
11. Rohwer N., Welzel M., Daskalow K, Pfander D., Wiedenmann B., Detjen K., Cramer T. (2008) Cancer Res., 68, 10113-10120.
12. Tevyashova A.N., Shtil A.A., Olsufyeva E.N., Simonova V.S., Samusenko A.V., Preobrazhenskaya M.N. (2004) J. Antibiot. (Tokyo), 57, 143-150.
13. Kozlova N.I., Morozevich G.E., Chubukina A.N., Shtil A.A., Berman A.E. (2004) EXCLI J., 3, 68-81.
14. Rozzo C., Chiesa V, Caridi G., Pagnan G., Ponzoni M. (1997) Int. J. Cancer, 70, 688-698.
15. Morozevich G., Kozlova N, Cheglakov L, Ushakova N, Berman A. (2009) Cell Cycle, 8, 2219-2225.
16. Kuzuya M., Satake S., Ramos M.A., Kanda S., Koike T., Yoshino K., Ikeda S., Iguchi A. (1999) Exp. Cell Res, 248, 498-508.
17. Taga T., Suzuki A., Gonzalez-Gomez I., Gilles F.H., Stins M., Shimada H., Barsky L., Weinberg K.I., Laug W.E. (2002) Int J. Cancer, 98, 690-697.
18. Koistinen P., Ahonen M., Kahari V.M., Heino J. (2004) Int. J. Cancer., 112, 61-70.
19. Matter M.L., Ruoslahti E. (2001) J. Biol. Chem., 276, 27757-27763.
20. Plath T., Detjen K, Welzel M., von Marschall Z., Murphy D., Schirner M., Wiedenmann B., Rosewicz S. (2000) J. Cell Biol., 150, 1467-1477.
21. Rohwer N., Welzel M., Daskalow K, Pfander D., Wiedenmann B., Detjen K, Cramer T. (2008) Cancer Res, 68, 10113-10120.
22. Bachelder R.E., Marchetti A., Falcioni R., Soddu S., Mercurio A.M. (1999) J. Biol. Chem., 274, 20733-20737.
23. Persons D.L., Yazlovitskaya E.M., Pelling J.C. (2000) J. Biol. Chem., 275, 35778-35785.
24. Schmidt M., Hövelmann S., Beckers T.L. (2002) Br. J. Cancer, 87, 924-932.
25. Vitolo M.I., Weiss M.B., Szmacinski M., Tahir K, Waldman T., Park BM., Martin S.S., Weber D.J., Bachman K.E. (2009) Cancer Res., 69, 8275-8283.